[^1]
| Property | Value |
|----------|-------|
| Protein Name | Collagen type IV alpha-2 chain |
| Aliases | COL4A2, Collagen IV α2 |
| Gene | COL4A2 |
| UniProt ID | P08572 |
| PDB IDs | 1LI1 (collagen IV NC1 domain) |
| Molecular Weight | ~168 kDa (precursor) |
| Amino Acids | 1,712 |
| Protein Family | Collagen superfamily, type IV (network-forming) |
| Subcellular Localization | Extracellular matrix (basement membrane) |
| Post-translational Modifications | Signal peptide cleavage, proline/lysine hydroxylation, glycosylation, NC1 domain cross-linking |
Collagen type IV alpha-2 chain is a protein encoded by the COL4A2 gene. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target.
Collagen IV α2 is a large structural protein with the characteristic collagen triple-helical organization. It assembles with two Collagen IV α1 chains to form the α1α1α2(IV) protomer, the predominant type IV collagen isoform in most basement membranes including the cerebrovascular basement membrane.
¶ Domain Architecture
- Signal peptide (aa 1-27) — Directs the nascent chain to the endoplasmic reticulum for secretion
- 7S domain (aa 28-174) — N-terminal domain that mediates lateral association of four protomers into antiparallel tetramers stabilized by disulfide bonds and lysyl oxidase-mediated cross-links
- Triple-helical collagenous domain (aa 175-1,433) — The major structural region; composed of ~1,260 amino acids with the characteristic Gly-X-Y repeat. Contains ~22 interruptions in the Gly-X-Y repeat that introduce flexibility and serve as binding sites for cell surface receptors (integrins), proteases (MMPs), and other ECM components
- NC1 (Non-Collagenous 1) domain (aa 1,434-1,712) — C-terminal globular domain that initiates chain selection and trimerization; mediates NC1-NC1 dimerization of protomers to form the characteristic collagen IV network; contains a sulfilimine bond (Met-Hyl cross-link) catalyzed by peroxidasin
Collagen IV network assembly follows a hierarchical pathway:
- Chain selection and trimerization — NC1 domains of two α1(IV) and one α2(IV) chains associate in the ER, nucleating triple helix formation that zips from C- to N-terminus
- Proline hydroxylation — Prolyl-4-hydroxylase hydroxylates proline residues to hydroxyproline, stabilizing the triple helix at body temperature
- Lysine hydroxylation and glycosylation — Lysyl hydroxylase modifies specific lysine residues; galactose and glucose are added
- Secretion — The procollagen protomer is secreted via large COPII vesicles (requires TANGO1 and HSP47 chaperone)
- 7S tetramerization — Four protomers associate at their N-terminal 7S domains, forming antiparallel tetramers
- NC1 dimerization — C-terminal NC1 hexamers (two trimers) form end-to-end dimers via sulfilimine bonds catalyzed by peroxidasin
- Lateral interactions — Protomers associate side-to-side via the triple-helical domain, forming a sheet-like network
¶ Gly-X-Y Repeat and Disease Mutations
The Gly-X-Y repeat in the collagenous domain requires glycine at every third position because only glycine is small enough to fit in the interior of the triple helix. Mutations replacing glycine with bulkier amino acids (Gly→Arg, Gly→Asp, Gly→Glu) destabilize the triple helix and are the most common cause of COL4A2-related disease.
Collagen IV α1α1α2 is the primary structural component of the cerebrovascular basement membrane and is essential for BBB integrity:
- Endothelial support — Provides the substrate for endothelial cell adhesion via α1β1 and α2β1 integrin receptors
- Pericyte anchoring — Pericytes attach to the basement membrane via integrin and dystroglycan complexes; collagen IV is the primary anchoring substrate
- Astrocyte endfoot attachment — Astrocyte endfeet contact the abluminal basement membrane through dystroglycan and aquaporin-4 complexes
- Selective permeability — The collagen IV network acts as a charge- and size-selective filter, restricting passage of plasma proteins
- Growth factor reservoir — Binds and presents VEGF, PDGF-BB, and FGF-2 to regulate angiogenesis and vessel stability
The basement membrane serves as the conduit for perivascular (glymphatic) clearance of interstitial solutes including amyloid-beta:
- Interstitial fluid drains along perivascular basement membranes in the reverse direction of blood flow
- Collagen IV provides the structural channel for this drainage
- Basement membrane thickening or disruption (as in COL4A2 mutations, aging, or hypertension) impairs drainage
- Impaired perivascular drainage promotes Aβ accumulation in vessel walls, leading to cerebral amyloid angiopathy (CAA)
COL4A2 protein dysfunction causes progressive CSVD through:
- ER retention of misfolded procollagen — Glycine substitution mutations prevent proper triple helix folding; misfolded protomers accumulate in the ER, triggering the unfolded protein response (UPR)))))))))))))))))))
- Reduced basement membrane deposition — Both the mutant and wild-type chains are retained in the ER (dominant-negative effect), reducing overall collagen IV in the basement membrane
- Basement membrane thinning — Reduced collagen IV weakens the structural integrity of cerebrovascular basement membranes
- Vessel wall fragility — Weakened vessels are prone to dilation, microaneurysm formation, and rupture (hemorrhage)
- BBB breakdown — Compromised basement membrane allows plasma protein leakage, driving perivascular inflammation and white matter damage
Chronic COL4A2-related vascular dysfunction contributes to neurodegeneration through:
- Chronic hypoperfusion — Small vessel disease reduces cerebral blood flow, causing chronic ischemia that damages white matter and promotes neuronal loss
- Neuroinflammation — BBB leakage admits plasma proteins (fibrinogen, thrombin, albumin) that activate microglia and drive inflammatory cascades
- Impaired Aβ clearance — Basement membrane dysfunction disrupts perivascular Aβ drainage, promoting amyloid deposition
- Mixed pathology dementia — Vascular and neurodegenerative pathologies (Aβ plaques, tau tangles, vascular lesions) frequently co-occur and synergize
Collagen IV undergoes age-related modifications that compound genetic vulnerability:
- Cross-link accumulation — Advanced glycation end-products (AGEs) cross-link collagen IV, increasing basement membrane stiffness
- Thickening — Basement membranes thicken with age, impairing perivascular drainage
- Fragmentation — MMP-mediated degradation fragments collagen IV, releasing bioactive matrikine peptides (tumstatin, canstatin, arresten)
- Reduced turnover — Collagen IV half-life is extremely long (>10 years); accumulated damage accumulates over decades
Proteolytic cleavage of collagen IV α2 generates biologically active fragments:
| Fragment |
Source Domain |
Activity |
Relevance |
| Canstatin |
NC1 domain of α2(IV) |
Anti-angiogenic, pro-apoptotic |
May limit pathological angiogenesis in tumors and CNS |
| Tumstatin |
NC1 domain of α3(IV) |
Anti-angiogenic (from related chain) |
Comparison: different α chain |
| Arresten |
NC1 domain of α1(IV) |
Anti-angiogenic (from partner chain) |
Produced from same protomer |
Canstatin (from α2 NC1) inhibits endothelial cell proliferation and tube formation through integrin αvβ3 and αvβ5 binding, potentially influencing cerebrovascular repair.
| Approach |
Target |
Status |
| Blood pressure control |
Reduce ICH risk in mutation carriers |
Standard of care |
| Chemical chaperones (4-PBA) |
Reduce ER stress from misfolded procollagen |
Preclinical (cell models) |
| Collagen IV supplementation |
Restore basement membrane integrity |
Experimental |
| MMP inhibitors |
Prevent basement membrane degradation |
Preclinical |
| Anti-AGE therapies |
Reduce collagen IV cross-linking with aging |
Clinical trials (diabetic nephropathy) |
| Gene therapy |
Replace mutant COL4A2 |
Very early stage |